Home / Health / Cancer Drug Prices Soar 50% Amid Shortages
Cancer Drug Prices Soar 50% Amid Shortages
13 Jun
Summary
- National Pharmaceutical Pricing Authority approved 50% price hike for critical cancer drugs.
- Carboplatin and Cisplatin prices increased due to escalating raw material costs.
- Prices of anti-tetanus and childhood vaccines also revised for availability.
In a significant move impacting healthcare access, India's National Pharmaceutical Pricing Authority (NPPA) has sanctioned a 50% rise in the ceiling prices for two vital cancer drugs, Carboplatin and Cisplatin. This decision was made on Thursday during the NPPA's 147th meeting, where extraordinary powers were invoked to address critical drug shortages.
The authority cited sharp increases and volatility in the prices of active pharmaceutical ingredients as the primary drivers for the price adjustment. Manufacturers had previously raised concerns about the rising costs and potential supply issues for these widely used chemotherapy medicines.
Beyond cancer treatments, the NPPA also approved a one-time 50% price increase for anti-tetanus immunoglobulin injections. Furthermore, ceiling prices for BCG, measles, and measles-rubella vaccines were revised, acknowledging their public health importance and the limited number of manufacturers.
This decisive action by the NPPA aims to prevent shortages of life-saving medicines and vaccines, balancing affordability with the commercial viability of production to ensure continued access for patients.
